AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Resmed DRC

37.170

+0.2700.73%

Volume:160.29K

Turnover:5.95M

Market Cap:54.50B

PE:28.89

High:37.320

Open:36.850

Low:36.720

Close:36.900

Loading ...

Overview Company News Filings

Q3 2025 Resmed Inc Earnings Call

Thomson Reuters StreetEvents

ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market

ResMed shares jump 8% on strong Q3 update

Stock Track | ResMed Shares Soar 5.68% on Strong Q3 Earnings, Beating Analyst Expectations

Stock Track | ResMed Soars 5.68% on Strong Q3 Earnings and Revenue Beat

ResMed Posts Higher Fiscal Q3 Earnings, Revenue

MT Newswires Live

Resmed Posts Fiscal Q3 Non-GAAP EPS of $2.37, Revenue of $1.29 Billion

MT Newswires Live

What would Warren Buffett do with ASX shares right now?

Here's What Key Metrics Tell Us About ResMed (RMD) Q3 Earnings

ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates

ResMed: Fiscal Q3 Earnings Snapshot

Associated Press Finance

ResMed Inc. Stock Rises Tuesday, Still Underperforms Market

Earnings To Watch: ResMed (RMD) Reports Q1 Results Tomorrow

Press Release: Resmed Names Salli Schwartz as Chief Investor Relations Officer

ResMed Is Maintained at Overweight by Keybanc

Earnings Preview: InMode (INMD) Q1 Earnings Expected to Decline

The easy way to build significant wealth with ASX shares

What Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings

ResMed Inc. Stock Falls Wednesday, Still Outperforms Market

ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RMD.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RMD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","market":"AU","secType":"STK","nameCN":"Resmed DRC","latestPrice":37.17,"timestamp":1746152054906,"preClose":36.9,"halted":0,"volume":160294,"delay":0,"nameEN":"Resmed DRC","floatShares":145691036,"shares":1466188140,"eps":1.2866961852967278,"marketStatus":"Trading","change":0.27,"latestTime":"05-02 12:14:17 AEST","open":36.85,"high":37.32,"low":36.72,"amount":5946666,"amplitude":0.01626,"askPrice":37.21,"askSize":1297,"bidPrice":37.18,"bidSize":41,"shortable":3,"etf":0,"ttmEps":1.2866961852967278,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1746165600000},"marketStatusCode":2,"adr":0,"adrRate":1,"exchange":"ASX","adjPreClose":36.9,"dividendRate":0.008314,"openAndCloseTimeList":[[1746144000000,1746165600000]],"volumeRatio":0.206887,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","floatShares":145691036,"roa":"14.01%","roe":"25.81%","lyrEps":0.97477,"volumeRatio":0.206887,"shares":1466188140,"dividePrice":0.307247,"high":37.32,"amplitude":0.01626,"preClose":36.9,"low":36.72,"week52Low":26.946,"pbRate":"6.30","psRate":"6.96","week52High":40.661,"institutionHeld":0,"latestPrice":37.17,"committee":-0.938714,"eps":1.2866961852967278,"divideRate":0.008314,"volume":160294,"delay":0,"ttmEps":1.2866961852967278,"open":36.85,"prevYearClose":36.689,"prevWeekClose":36.08,"prevMonthClose":36.68,"prevQuarterClose":34.96,"fiveDayClose":36.08,"twentyDayClose":35.63,"sixtyDayClose":38.874},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RMD.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529498150","title":"Q3 2025 Resmed Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2529498150","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529498150?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:21","pubTimestamp":1745497282,"startTime":"0","endTime":"0","summary":"Michael Farrell; Chairman of the Board, Chief Executive Officer; Resmed Inc. Salli Schwartz; Chief Investor Relations Officer; ResMed Inc. Dan Hurren; Analyst; MST Financial Services Pty Ltd. Greetings, and welcome to the Q3 fiscal year 2025 ResMed earnings conference call. My name is Kevin, and I'll be your operator for today's call.  And also, please note this conference call is being recorded.  Let me hand the call over to ResMed's Chairman and CEO, Mick Farrell; for a brief introduction of Sally Schwartz, who recently joined the company as Chief Investor Relations Officer. Mick, please go ahead.Thank you, Kevin. I'm very excited to have Sally join the ResMed team, our newest ResMedian. She joined us earlier this week and brings more than two decades of experience across capital markets, health care and technology.We look forward to Sally helping us to take Investor Relations to the next level here at ResMed, providing clarity, transparency and long-term alignment amongst current an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q3-2025-resmed-inc-earnings-122122573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RMD.AU","RMD"],"gpt_icon":0},{"id":"2529980971","title":"ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2529980971","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529980971?lang=en_us&edition=fundamental","pubTime":"2025-04-24 19:24","pubTimestamp":1745493840,"startTime":"0","endTime":"0","summary":"ResMed Inc.’s RMD adjusted earnings per share  in the third quarter of fiscal 2025 were $2.37, up 11.3% year over year. The metric beat the Zacks Consensus Estimate by 0.4%. . The adjustments include certain non-recurring expenses/benefits like the amortization of acquired intangibles, along with the income tax effect on those adjustments.GAAP EPS in the reported quarter was $2.48, up 21.6% from the year-ago level.Following the announcement, shares of RMD rose 2.6% in the after-market trading yesterday.On a reported basis, revenues increased 7.5% year over year  to $1.29 billion. The figure topped the Zacks Consensus Estimate by 0.5%.ResMed operated through two reporting units, namely Sleep and Respiratory Care and Software as a Service .Selling, general and administration expenses rose 6.7% year over year to $245.3 million. Research and development expenses increased 8.9% to $83.9 million. The adjusted operating income was $444.6 mil","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/resmed-q3-earnings-revenues-beat-112400694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RMD","RMD.AU"],"gpt_icon":0},{"id":"2529605626","title":"ResMed shares jump 8% on strong Q3 update","url":"https://stock-news.laohu8.com/highlight/detail?id=2529605626","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529605626?lang=en_us&edition=fundamental","pubTime":"2025-04-24 08:25","pubTimestamp":1745454324,"startTime":"0","endTime":"0","summary":"ResMed Inc. (ASX: RMD) shares are charging higher on Thursday. In morning trade, the sleep disorder treatment company's shares are up 8% to $35.84. This follows the release of another strong quarterly","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/24/resmed-shares-jump-8-on-strong-q3-update/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU2008162690.USD","BK4585","RMD.AU","BK4082","BK4504","RMD","LU0170899867.USD","BK7501","LU2177674079.SGD","BK4567","BK7007","BK4548","BK4588"],"gpt_icon":0},{"id":"1120867633","title":"Stock Track | ResMed Shares Soar 5.68% on Strong Q3 Earnings, Beating Analyst Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=1120867633","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120867633?lang=en_us&edition=fundamental","pubTime":"2025-04-24 08:08","pubTimestamp":1745453312,"startTime":"0","endTime":"0","summary":"Shares of ResMed Inc.  surged 5.68% in Thursday's pre-market trading session following the release of its impressive fiscal third-quarter results for 2025. The medical device company, specializing in sleep apnea and respiratory care, outperformed analyst expectations with robust revenue growth and improved profitability.ResMed reported non-GAAP earnings per share of $2.37, surpassing the Zacks Consensus Estimate of $2.36 and marking an 11.3% increase from $2.13 in the same quarter last year. The","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["RMD.AU"],"gpt_icon":1},{"id":"1125559105","title":"Stock Track | ResMed Soars 5.68% on Strong Q3 Earnings and Revenue Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1125559105","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125559105?lang=en_us&edition=fundamental","pubTime":"2025-04-24 08:08","pubTimestamp":1745453310,"startTime":"0","endTime":"0","summary":"ResMed Inc.  shares surged 5.68% in Thursday's intraday trading session following the release of its strong fiscal third-quarter results that exceeded analyst expectations.The medical device company, which specializes in sleep apnea and respiratory care, reported a non-GAAP earnings per share  of $2.37 for the quarter ended March 31, 2025. This figure surpassed the Zacks Consensus Estimate of $2.36 per share and represented a significant improvement from $2.13 per share in the same quarter last ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | ResMed Soars 5.68% on Strong Q3 Earnings and Revenue Beat","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["RMD.AU"],"gpt_icon":0},{"id":"2529698446","title":"ResMed Posts Higher Fiscal Q3 Earnings, Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2529698446","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529698446?lang=en_us&edition=fundamental","pubTime":"2025-04-24 07:13","pubTimestamp":1745450034,"startTime":"0","endTime":"0","summary":"ResMed  reported Thursday fiscal third-quarter earnings of $2.37 per diluted share on a non-GAAP basis, up from $2.13 per diluted share a year earlier.On a GAAP basis, diluted earnings per share rose to $2.58 from $2.04 year on year, the filing said.Analysts polled by Visible Alpha were expecting EPS of $2.22.Revenue for the three months ended March 31 was $1.29 billion, up 8% from $1.19 billion in the same period last year. Analysts surveyed by Visible Alpha expected $1.27 billion.The board declared a quarterly dividend of $0.053 per share, up from the $0.048 in the previous reported period, payable on June 12 to shareholders on record as of May 8.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RMD","RMD.AU"],"gpt_icon":0},{"id":"2529166059","title":"Resmed Posts Fiscal Q3 Non-GAAP EPS of $2.37, Revenue of $1.29 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2529166059","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529166059?lang=en_us&edition=fundamental","pubTime":"2025-04-24 06:51","pubTimestamp":1745448670,"startTime":"0","endTime":"0","summary":"Resmed Posts Fiscal Q3 Non-GAAP EPS of $2.37, Revenue of $1.29 Billion","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RMD","RMD.AU"],"gpt_icon":0},{"id":"2529569525","title":"What would Warren Buffett do with ASX shares right now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2529569525","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529569525?lang=en_us&edition=fundamental","pubTime":"2025-04-24 06:39","pubTimestamp":1745447963,"startTime":"0","endTime":"0","summary":"It is fair to say that there's been no shortage of fear on the market lately. Trade tensions, volatility, and headlines predicting the next recession have sent many investors running for the sidelines. But if there's one person who would see today's environment as ripe with opportunity, it is Warren Buffett. While the Oracle of Omaha doesn't typically invest in the ASX, his investment playbook is universal — and it is perfectly suited to moments like these. So, if Buffett were eyeing the ASX today, what might he do?He probably wouldn't even notice. His holding periods often span 20–30 years, and his performance has been built on patience, not prediction. That's a good reminder for any ASX investor. Foolish takeaway Warren Buffett may not be browsing the ASX boards, but his principles can still guide you through turbulent times. Buy quality, ignore the noise, and think long term. In fact, Buffett said it best when he said:  Opportunities come infrequently. When it rains gold, put out th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/24/what-would-warren-buffett-do-with-asx-shares-right-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IE00BWXC8680.SGD","BK7508","LU0648001328.SGD","LU1280957306.USD","LU0787776722.HKD","LU0683600562.USD","IE00B775SV38.USD","IE00BK4W5M84.HKD","LU1914381329.SGD","LU0154236417.USD","IE00BK4W5L77.USD","LU0417517546.SGD","IE00B1XK9C88.USD","RMD.AU","LOV.AU","LU0170899867.USD","BK4550","BK4588","LU0234570918.USD","IE00BKDWB100.SGD","LU0256863811.USD","BK7128","IE000M9KFDE8.USD","BK4585","IE00BJLML261.HKD","LU0053666078.USD","LU1363072403.SGD","LU1571399168.USD","BK4581","BK7016","BK7501","BK7503","IE0034235303.USD","BK4534","CSL.AU","TNE.AU","LU0149725797.USD","LU0971096721.USD","BK7067","LU1074936037.SGD","LU0048573561.USD","LU0640476718.USD","LU0980610538.SGD","LU0742534661.SGD","LU0130102774.USD","BRK.B","BK4533","IE00B3S45H60.SGD","LU0251131958.USD","BK7511"],"gpt_icon":1},{"id":"2529699346","title":"Here's What Key Metrics Tell Us About ResMed (RMD) Q3 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2529699346","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529699346?lang=en_us&edition=fundamental","pubTime":"2025-04-24 06:00","pubTimestamp":1745445606,"startTime":"0","endTime":"0","summary":"ResMed  reported $1.29 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 7.9%. EPS of $2.37 for the same period compares to $2.13 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.28 billion, representing a surprise of +0.53%. The company delivered an EPS surprise of +0.42%, with the consensus EPS estimate being $2.36.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.U.S., Canada, and Latin America- Masks and other: $326.70 million versus $318.76 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +13.4% change.Combined Europe, Asia, and other markets- Total: $381.30 million versus $377.86 million estimated by four analysts on average","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-key-metrics-tell-us-220006611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD","RMD.AU"],"gpt_icon":0},{"id":"2529366077","title":"ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2529366077","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529366077?lang=en_us&edition=fundamental","pubTime":"2025-04-24 05:15","pubTimestamp":1745442909,"startTime":"0","endTime":"0","summary":"ResMed  came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $2.13 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.42%. A quarter ago, it was expected that this maker of medical products for respiratory disorders would post earnings of $2.30 per share when it actually produced earnings of $2.43, delivering a surprise of 5.65%.Over the last four quarters, the company has surpassed consensus EPS estimates four times.ResMed , which belongs to the Zacks Medical - Products industry, posted revenues of $1.29 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.53%. This compares to year-ago revenues of $1.2 billion. The company has topped consensus revenue estimates four times over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can have a mat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/resmed-rmd-q3-earnings-revenues-211509546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD.AU","RMD"],"gpt_icon":1},{"id":"2529663499","title":"ResMed: Fiscal Q3 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2529663499","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529663499?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:19","pubTimestamp":1745439540,"startTime":"0","endTime":"0","summary":"SAN DIEGO  — SAN DIEGO  — ResMed Inc.  on Wednesday reported fiscal third-quarter profit of $365 million.On a per-share basis, the San Diego-based company said it had profit of $2.48. Earnings, adjusted for pretax gains, came to $2.37 per share.The results exceeded Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $2.36 per share.The maker of medical products for respiratory disorders posted revenue of $1.29 billion in the period, which also beat Street forecasts. Seven analysts surveyed by Zacks expected $1.28 billion.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/resmed-fiscal-q3-earnings-snapshot-201900205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD.AU","RMD"],"gpt_icon":0},{"id":"2529550074","title":"ResMed Inc. Stock Rises Tuesday, Still Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2529550074","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529550074?lang=en_us&edition=fundamental","pubTime":"2025-04-23 04:56","pubTimestamp":1745355360,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of ResMed Inc.  advanced 1.52% to $214.08 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 2.51% to 5,287.76 and the Dow Jones Industrial Average  rising 2.66% to 39,186.98.ResMed Inc. closed 18.62% below its 52-week high of $263.05, which the company reached on January 30th.Trading volume  eclipsed its 50-day average volume of 1.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 22, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD","RMD.AU"],"gpt_icon":0},{"id":"2529588137","title":"Earnings To Watch: ResMed (RMD) Reports Q1 Results Tomorrow","url":"https://stock-news.laohu8.com/highlight/detail?id=2529588137","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529588137?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:02","pubTimestamp":1745323322,"startTime":"0","endTime":"0","summary":"Medical device company ResMed  will be announcing earnings results tomorrow after market close. Here’s what to look for.ResMed beat analysts’ revenue expectations by 1% last quarter, reporting revenues of $1.28 billion, up 10.3% year on year. It was a strong quarter for the company, with a narrow beat of analysts’ constant currency revenue estimates and a decent beat of analysts’ EPS estimates.Is ResMed a buy or sell going into earnings?This quarter, analysts are expecting ResMed’s revenue to grow 7.8% year on year to $1.29 billion, in line with the 7.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.36 per share.When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/earnings-watch-resmed-rmd-reports-120202022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD","NEOG","RMD.AU","ABT"],"gpt_icon":0},{"id":"2529355883","title":"Press Release: Resmed Names Salli Schwartz as Chief Investor Relations Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529355883","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529355883?lang=en_us&edition=fundamental","pubTime":"2025-04-22 05:00","pubTimestamp":1745269200,"startTime":"0","endTime":"0","summary":"Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she led the company's investor engagement strategy, representing the company's response to shareholders' perspectives on corporate strategy, capital allocation, and financial performance. She was also a member of Illumina's Corporate Social Responsibility Executive Steering Committee and its Transformation Office.Resmed  creates life-changing health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent s","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK4585","LU0170899867.USD","BK7007","BK4548","BK4588","LU2008162690.USD","RMD","LU2177674079.SGD","RMD.AU","BK4082","BK4567","BK4504"],"gpt_icon":0},{"id":"2529389876","title":"ResMed Is Maintained at Overweight by Keybanc","url":"https://stock-news.laohu8.com/highlight/detail?id=2529389876","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529389876?lang=en_us&edition=fundamental","pubTime":"2025-04-21 23:12","pubTimestamp":1745248320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 21, 2025 11:12 ET (15:12 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD","RMD.AU"],"gpt_icon":0},{"id":"2529438973","title":"Earnings Preview: InMode (INMD) Q1 Earnings Expected to Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2529438973","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529438973?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:00","pubTimestamp":1745244020,"startTime":"0","endTime":"0","summary":"The market expects InMode  to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 28. On the other hand, if they miss, the stock may move lower.While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.This maker of cosmetic surgery devices is expected to post quarterly earnings of $0.33 per share in its upcoming report, which represents a year-over-year change of -26.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/earnings-preview-inmode-inmd-q1-140020782.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RMD.AU","INMD","RMD"],"gpt_icon":0},{"id":"2528102564","title":"The easy way to build significant wealth with ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2528102564","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528102564?lang=en_us&edition=fundamental","pubTime":"2025-04-19 05:12","pubTimestamp":1745010720,"startTime":"0","endTime":"0","summary":"A few quality ASX shares, like ResMed Inc  or Lovisa Holdings Ltd , combined with some global exposure via ASX ETFs like iShares S&P 500 ETF  or Betashares Global Quality Leaders ETF , could give you a diversified, growth-focused portfolio that does most of the work for you. It most probably won't double overnight. But it will grow. And in 10 or 20 years, you might just look back and realise that your boring investments were the smartest decisions you ever made.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/19/the-easy-way-to-build-significant-wealth-with-asx-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7155","BK7128","LOV.AU","BK7007","BK7099","BK7503","BK7510","BK7016","BK7501","BRN.AU","RMD.AU","TNE.AU","GMG.AU","QLTY.AU","IVV.AU"],"gpt_icon":1},{"id":"2528449767","title":"What Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2528449767","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528449767?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:15","pubTimestamp":1744895722,"startTime":"0","endTime":"0","summary":"Wall Street analysts forecast that ResMed  will report quarterly earnings of $2.36 per share in its upcoming release, pointing to a year-over-year increase of 10.8%. It is anticipated that revenues will amount to $1.28 billion, exhibiting an increase of 7.3% compared to the year-ago quarter.The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.Analysts expect 'Combined Europe, Asia, and other markets- Total' to come in at $3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/analyst-projections-key-metrics-reveal-131522137.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD.AU","RMD"],"gpt_icon":0},{"id":"2528420308","title":"ResMed Inc. Stock Falls Wednesday, Still Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2528420308","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528420308?lang=en_us&edition=fundamental","pubTime":"2025-04-17 04:58","pubTimestamp":1744837080,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of ResMed Inc.  shed 1.16% to $211.49 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index  falling 2.24% to 5,275.70 and Dow Jones Industrial Average  falling 1.73% to 39,669.39.This was the stock's second consecutive day of losses.ResMed Inc. closed 19.60% below its 52-week high of $263.05, which the company reached on January 30th.Trading volume  remained 126,305 below its 50-day average volume of 1.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 16, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD.AU","RMD"],"gpt_icon":0},{"id":"2528244912","title":"ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2528244912","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528244912?lang=en_us&edition=fundamental","pubTime":"2025-04-16 22:00","pubTimestamp":1744812056,"startTime":"0","endTime":"0","summary":"Wall Street expects a year-over-year increase in earnings on higher revenues when ResMed  reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 23. On the other hand, if they miss, the stock may move lower.While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.This maker of medical products for respiratory disorders is expected to post quarterly earnings of $2.36 per share in its upcoming report, which represents a year-over-year change of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/resmed-rmd-reports-next-week-140056809.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RMD.AU","RMD"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RMD.AU\",params:#limit:5,,,undefined,":[{"date":"2025-05-07","symbol":"RMD.AU","amount":0.053,"announcedDate":"2025-04-24","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-05-08","defaultRemindTime":1746576000000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-12","payableDate":"2025-05-08","currency":"USD","dateTimestamp":1746540000000,"payDate":"2025-06-12"},{"date":"2025-02-12","symbol":"RMD.AU","amount":0.053,"announcedDate":"2025-01-31","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-02-13","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-20","payableDate":"2025-02-13","currency":"USD","dateTimestamp":1739278800000,"payDate":"2025-03-20"},{"date":"2024-11-06","symbol":"RMD.AU","amount":0.053,"announcedDate":"2024-10-25","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-11-07","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-12","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730811600000,"payDate":"2024-12-12"},{"date":"2024-08-14","symbol":"RMD.AU","amount":0.053,"announcedDate":"2024-08-02","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-08-15","defaultRemindTime":1723593600000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-19","payableDate":"2024-08-15","currency":"USD","dateTimestamp":1723557600000,"payDate":"2024-09-19"},{"date":"2024-05-08","symbol":"RMD.AU","amount":0.048,"announcedDate":"2024-04-26","type":"dividend","market":"AU","newRecordDate":"2024-05-09","defaultRemindTime":1715126400000,"name":"Resmed DRC","recordDate":"2024-06-13","payableDate":"2024-05-09","currency":"USD","dateTimestamp":1715090400000,"payDate":"2024-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RMD.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-08-19","recordDate":"2020-08-20","paymentDate":"2020-09-24","value":0.039,"currency":"USD"},{"executeDate":"2020-11-11","recordDate":"2020-11-12","paymentDate":"2020-12-17","value":0.039,"currency":"USD"},{"executeDate":"2021-02-10","recordDate":"2021-02-11","paymentDate":"2021-03-18","value":0.039,"currency":"USD"},{"executeDate":"2021-05-12","recordDate":"2021-05-13","paymentDate":"2021-06-17","value":0.039,"currency":"USD"},{"executeDate":"2021-08-18","recordDate":"2021-08-19","paymentDate":"2021-09-23","value":0.042,"currency":"USD"}]}}